Recent Quotes (30 days)

You have no recent quotes
chg | %

Concordia Healthcare Corp  

(Public, TSE:CXR)   Watch this stock  
Find more results for CXR
+0.90 (2.24%)
Delayed:   1:29PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 40.63 - 41.90
52 week 25.04 - 117.75
Open 41.75
Vol / Avg. 261,916.00/974,540.00
Mkt cap 2.05B
P/E     -
Div/yield 0.10/0.94
EPS -1.27
Shares 51.02M
Beta -2.91
Inst. own     -
Aug 11, 2016
Q2 2016 Concordia Healthcare Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 13, 2016
Q1 2016 Concordia Healthcare Corp Earnings Release
May 13, 2016
Q1 2016 Concordia Healthcare Corp Earnings Call
Apr 29, 2016
Concordia Healthcare Corp Ordinary Shareholders Meeting
Mar 24, 2016
Q4 2015 Concordia Healthcare Corp Earnings Call - Webcast
Mar 23, 2016
Q4 2015 Concordia Healthcare Corp Earnings Release

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -2.10% -7.46%
Operating margin 26.22% 20.41%
EBITD margin - 54.41%
Return on average assets -0.37% -1.00%
Return on average equity -1.72% -4.16%
Employees 214 -
CDP Score - -


277 Lakeshore Rd E Suite 302
+1-905-8425150 (Phone)
+1-905-8425154 (Fax)

Website links


Concordia Healthcare Corp. is a specialty pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its segments are Concordia North America, Concordia International, Orphan Drugs and Corporate cost centre. Its Concordia North America segment includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer. The Concordia International segment includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines. The Orphan Drugs segment includes Photofrin, which is for the treatment of certain forms of rare cancer. The Corporate cost centre segment includes centralized costs incurred by the Company.

Officers and directors

Mark L. Thompson Chairman of the Board, Chief Executive Officer, Founder
Age: 47
Wayne Kreppner President, Chief Operating Officer
Age: 41
Adrian de Saldanha Chief Financial Officer
Robert Altman Ph.D. President - Pinnacle Biologics Inc.
Age: 62
Arijit Mookerjee Managing Director, Chief Financial Officer - Operations
Leith Tessy Treasurer, Secretary
Age: 52
Jordan M. Kupinsky J.D. Lead Independent Director
Age: 42
Patrick Vink M.D. Director
Age: 51
Edward J. Borkowski CPA Independent Director
Age: 55
Douglas N. Deeth Independent Director
Age: 67